TRIFERIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRIFERIC (TRIFERIC).
Triferic (ferric pyrophosphate citrate) is an iron replacement agent that delivers iron directly to transferrin via the sodium-dependent phosphate transporter, bypassing the reticuloendothelial system, thereby increasing iron availability for erythropoiesis without increasing ferritin levels.
| Metabolism | Triferic is iron-carbohydrate complex; iron is incorporated into hemoglobin or stored as ferritin; not metabolized by cytochrome P450. |
| Excretion | Ferric carboxymaltose is eliminated primarily via renal excretion of the iron-carbohydrate complex, with approximately 60-70% of the administered iron dose excreted in urine within 24 hours. The remaining 30-40% is retained in the body, incorporated into hemoglobin and iron stores, with minimal biliary or fecal excretion. |
| Half-life | The terminal elimination half-life of ferric carboxymaltose is approximately 7-12 hours for the iron-carbohydrate complex. However, the clinical context involves redistribution of iron to stores and erythron, with a functional half-life of about 14-21 days for iron utilization. |
| Protein binding | Ferric carboxymaltose is composed of iron complexed with carboxymaltose. Iron is transported bound to transferrin (approximately 30% saturated under normal conditions). The iron-carbohydrate complex itself is stable and does not bind significantly to plasma proteins; the released iron is rapidly bound to transferrin. Overall, iron exhibits >99% binding to transferrin in plasma. |
| Volume of Distribution | The volume of distribution (Vd) for ferric carboxymaltose is approximately 2-3 L/kg, reflecting extensive distribution into tissues including bone marrow and reticuloendothelial system. |
| Bioavailability | Ferric carboxymaltose is administered intravenously; bioavailability is 100% by this route. Oral administration is not applicable due to instability and lack of absorption as intact complex. |
| Onset of Action | Intravenous administration: Clinical effects, such as increase in hemoglobin, are typically observed within 1-2 weeks. Iron parameters (e.g., serum ferritin) increase within 24 hours post-dose. |
| Duration of Action | The duration of action for a single IV dose is approximately 2-4 weeks, corresponding to the period of iron utilization for erythropoiesis. Repeat dosing may be required based on ongoing iron needs. |
For iron deficiency anemia: 1 tablet (30 mg elemental iron as ferric pyrophosphate citrate) twice daily, 30 minutes before meals, administered orally.
| Dosage form | POWDER |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min; use with caution and monitor iron status in GFR <30 mL/min due to potential iron overload. |
| Liver impairment | No studies in hepatic impairment; use with caution in Child-Pugh C due to possible altered iron metabolism. |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established in children <18 years. |
| Geriatric use | No specific dose adjustment; consider renal function and potential for iron accumulation in elderly with chronic conditions. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRIFERIC (TRIFERIC).
| Breastfeeding | Minimal excretion into breast milk due to lack of systemic absorption. M/P ratio unknown. Considered safe during breastfeeding. |
| Teratogenic Risk | No known teratogenic risk in any trimester. Triferic (ferric pyrophosphate citrate) is not absorbed systemically when given via hemodialysis, thus exposure to fetus is negligible. No studies in pregnant women; animal studies show no harm. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Known hypersensitivity to ferric pyrophosphate citrate or any component","Evidence of iron overload (serum ferritin >500 ng/mL or transferrin saturation >50%)","Non-hemodialysis dependent chronic kidney disease"]
| Precautions | ["Hypersensitivity reactions including anaphylaxis","Iron overload with hemosiderosis","Hypotension during hemodialysis","May increase risk of infections due to iron availability for pathogens"] |
Loading safety data…
| Monitor hemoglobin, hematocrit, serum iron, ferritin, and transferrin saturation per standard of care for iron deficiency in dialysis patients. No specific fetal monitoring required. |
| Fertility Effects | No known effects on fertility. Iron replacement may improve fertility if anemia is contributing factor. |